Novel Therapy Shown Effective for Atopic Dermatitis

ORLANDO, Fla. — In a phase 3 atopic dermatitis (AD) trial, rocatinlimab, a novel therapy that targets T cells expressing the OX40 receptor, showed efficacy on both coprimary and key secondary endpoints in treatment-experienced patients with long-standing moderate to severe disease. The efficacy of the drug appears to be derived from its ability to eliminate …